Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-389949 SAD and Food Interaction Study in Healthy Males
NCT02099071Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-389949 in asthma and chronic obstructive pulmonary disease (COPD) (8 cohorts), sponsored by Idorsia. Primary endpoints: Supine Systolic Blood Pressure at 60 hours, Standing Systolic Blood Pressure at 60 hours and 8 more. Started Nov 2011; status: completed.
02
Drugs
ACT-389949
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02099071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099071.